Page 8 - Second Genome News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Design Therapeutics Expands Board of Directors with Key Appointments June 07, 2021 16:05 ET | Source: Design Therapeutics, Inc. Design Therapeutics, Inc. Solana Beach, California, UNITED STATES CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appointments of industry veterans, Heather Behanna, Ph.D., principal of SR One, and Deepa Prasad, managing director of WestRiver Group, to its board of directors e...

Share this article Share this article ResearchAndMarkets.com's offering. The global human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth. However, a lack of expertise and inadeq...

Latest research on Global Human Micobiome Market report covers forecast and analysis on a worldwide, regional and country level. The study provides hi

Databridgemarketresearch.com Present “ Microbiome Sequencing Services Market– Industry Trends and Forecast to 2028” new report to its research database. Due to the potential of SWOT analysis and Porter’s Five Forces analysis in generating market research report, they are preferred by the businesses and hence also used while making this report. To structure such a world-class report, the combination of best industry insight, practical solutions, talent solutions and latest technology have been used. As today’s businesses demand the market research analysis to a great extent before ta...

Share this article Share this article BRISBANE, Calif., Jan. 25, 2021 /PRNewswire/ -- Second Genome, a leader in microbiome science, today announced the appointment of Susannah Cantrell, PhD, to the position of chief business officer, and Preeti G. Lal, PhD, to the position of chief scientific officer. Susannah Cantrell, PhD, joined Second Genome as chief business officer in November 2020. Dr. Cantrell has over 20 years of industry experience across global pipeline strategy, sales, operations, marketing and new product commercialization. Her experience covers multiple therapeutic areas inclu...